Eone Diagnomics: Despite huge losses and capital impairment in 2025, court-approved rehabilitation plan promises financial restructuring


  • 2025 revenue 7.9B KRW (down 41% from 13.5B in 2024), operating loss 1.6B, net loss 5.1B (improved from 73.1B loss in 2024)
  • Total assets 44.1B, total liabilities 66.5B → negative equity of 22.3B (complete capital impairment)
  • Auditor emphasized 'material uncertainty related to going concern', internal control opinion unqualified
  • Post-year-end: March 2026, Suwon Rehabilitation Court approved rehabilitation plan → debt-to-equity swap (~55.88%), stock consolidation (6:1), 165B KRW paid-in capital increase, 150B KRW bond issuance
  • Largest shareholder changed to Hamilly Consortium, expected normalization of financial structure
ADVERTISEMENT (250px+)

KOSDAQ Filing Information


  • Filing: Business Report (2025.12)
  • Company: Eone Diagnomics Genome Center (245620)
  • Submission: Eone Diagnomics Genome Center Co., Ltd.
  • Receipt: 04-08-2026
  • Consolidated section included